Biofilm Formation among Various Candida Species and its Role in Antifungal Resistance at Tertiary Care Centre, Jhalawar

Rajesh Bansal¹, Yogendra Kumar Tiwari², Vasudev Patidar³

INTRODUCTION

Candida infections have emerged as important public health problems with significant morbidity and mortality. The growing number of immunocompromised individuals as a result of the HIV pandemic and the use of long-term immunosuppressive therapy in cancer and organ transplant patients have favoured the increased incidence of Non albicans Candida species among hospitalized and immunosuppressed patients. Biofilm is one of the known virulence factors of Candida, an important pathogen and commensal. Microorganisms growing in a biofilm are associated with chronic and recurrent human infections and are highly resistant to antimicrobial agents. Early detection of biofilm production may be useful for clinical decision because of its suggestive property for potential pathogenic capacity of Candida isolates.

Biofilms are defined as microbial derived sessile communities characterized by the cells that are irreversibly attached to a substratum or to each other. They are embedded in a matrix of extracellular polymeric substances (EPS) they have produced and exhibit an altered phenotype with respect to growth rate and gene transcription. Within a biofilm, microorganisms communicate with each other by production of chemotactic particles or pheromones, a phenomenon called ‘quorum sensing’. Availability of key nutrients, chemotaxis towards surface, surface adhesins and presence of surfactants are some factors which influence biofilm formation. Microorganisms growing in a biofilm are intrinsically more resistant to antimicrobial agents than planktonic cells.

High antimicrobial concentrations are required to inactivate organisms growing in a biofilm, as antimicrobial resistance can increase to 1,000-fold. With the emergence of biofilm associated diseases, there are considerable diagnostic problems for the clinical laboratory, decreased antimicrobial susceptibility, false negative cultures, visible but not cultivable organisms or inappropriate specimen. The determination of biofilm production in Candida spp. may be important for the management of invasive infections. There are various methods to detect biofilm production. These include

• Tissue Culture Plate (TCP),
• Tube method (TM),
• Congo Red Agar method (CRA),

¹Senior Demonstrator, Department of Microbiology, ²Associate Professor and HOD, Department of Microbiology, ³Microbiologist, Department of Microbiology, Jhalawar Medical College, Jhalawar, India

Corresponding author: Dr Yogendra Kumar Tiwari, Qtr. No. IV/9, Medical College Campus, Jhalawar. (Raj) 326001, India

How to cite this article: Rajesh Bansal, Yogendra Kumar Tiwari, Vasudev Patidar. Biofilm formation among various candida species and its role in antifungal resistance at tertiary care centre, Jhalawar. International Journal of Contemporary Medical Research 2019;6(5):E1-E4.

DOI: http://dx.doi.org/10.21276/ijcmr.2019.6.5.25
• bioluminescent assay,
• piezoelectric sensors method and
• fluorescent microscopic examination.

Study by dag et al., 2010 reported that Tube method showed very good agreement for the isolates producing strong biofilm, whereas differentiation of isolates producing weak biofilm was difficult.\(^1\) By the Congo red method, classification of existing biofilm was problematic. Among the three methods studied, microtiter plate method may be suggested as the most sensitive method, which is easy to conduct and applicable as a routine process. Study aimed to investigate biofilm formation among candida species isolated from various clinical samples and its role in antifungal resistance.

**MATeRiAl And MeThodS**

A retrospective observational study was conducted from October 2017 to Jan 2019. A total of 630 various clinical samples received in Microbiology department from patients with suspected *Candida* infection were collected and processed. The various clinical samples were including respiratory samples (sputum, bronchial wash and tracheal secretions), various body fluids, blood, urine, ear discharge, invasive devices (endotracheal tube, catheter tip and suction tip) and vaginal discharge. Samples were processed by Gram staining, KOH mount and culture on SDA and BHI agar. Isolated yeasts were identified and speciated by germ tube test, chlamydomatospores formation on corn meal agar, colour production on CHROM agar, sugar fermentation test and sugar assimilation test.\(^1\) Antifungal susceptibility testing of the yeast isolates was performed by ‘Disc Diffusion Method’ including Amphotericin B (100 IU), Fluconazole (25μg), Nystatin (50μg), Ketoconazole (50μg), and Itraconazole (10μg) as per CLSI guidelines.\(^2\) Reference strains from quality control methods used were, • *Candida parapsilosis* ATCC 22019
• *Candida albicans* ATCC 90028
• *Candida tropicalis* ATCC 750
• *Candida krusei* ATCC 6258

Biofilm formation ability of yeast isolates were tested by Tube Adherence Test and Tissue Culture Plate Method.\(^3\)

**STATISTICAL ANALYSIS**

The data was statistically analysed using the statistical package for Social science (SPSS)/ 21.0 (Copyright © SPSS Inc.). Frequency of qualitative variables was calculated and correlation was tested by Chi-square test. Statistical significance was accepted at p <0.05.\(^4\)

**RESULTS**

Non *albicans candida* 204/313 (65.18%) were predominant isolates than *C. albicans* 109/313 (34.82%). Depending on the results of various test done for speciation, *C. Tropicalis* (46.33%) was predominant isolate followed by *C. Albicans* (34.82%), *C parapsilosis* (10.54%), *C. glabrata* (5.75%) and *C. krusei* (2.56%). *C. tropicalis* was major isolate among various clinical samples whereas candida albicans was predominant in body fluids (66.67%) and respiratory secretions (53.19%).

Tissue culture plate method (50.16%) was more sensitive than Tube method (29.07 %) for biofilm detection. Out of 313 isolates, 157 (50.16%) were found to be biofilm producers. Maximum biofilm production was obtained in blood samples (55.41%) followed by respiratory secretion (13.38%), Catheter tip (12.74%), pus (8.28%), vaginal (5.10%), urine (4.46%) and body fluids (0.64%) (graph-1).

Among Non *albicans Candida*, *Candida tropicalis* (52.86%) was most common Candida species to be isolated as biofilm producer followed by *C. Parapsilosis* (10.19%), *C. glabrata* (10.19%) and *C. krusei* (4.45%) while *C. albicans* was 35/157 (22.29%).

When *Candida* isolates were tested for biofilm formation capacity, biofilm production was most commonly observed for isolates of *C. glabrata* 16/18 (88.9%) and *C. krusei* 7/8 (87.5%) followed by *C. tropicalis* 87/145 (57.2%), *C. parapsilosis* 16/33 (48.5%) and *C. albicans* 35/109 (32.1%) isolates.

Antifungal resistance was observed more among biofilm producers. Fluconazole and (96.18%) and Ketoconazole (77.71%) were most resistant antifungal drugs in biofilm producers. Fluconazole and (96.18%) and Ketoconazole (77.71%) were most resistant antifungal drugs in antifungal resistance.

| Biofilm producers | Fluconazole | Ketoconazole | Itraconazole | Amphotericin B | Nystatin |
|-------------------|-------------|--------------|--------------|----------------|---------|
| +                 | No. | %  | No. | %  | No. | %  | No. | %  | No. | %  |
| Candida albicans  | 35  | 31 | 88.57 | 28 | 80.00 | 1  | 2.86 | 1  | 2.86 | 7  | 20.00 |
| Candida tropicalis| 83  | 82 | 98.80 | 58 | 69.88 | 4  | 4.82 | 7  | 8.43 | 20 | 24.10 |
| Candida parapsilosis| 16  | 16| 100.00 | 14 | 87.50 | 4  | 25.00 | 1  | 6.25 | 4  | 25.00 |
| Candida           | 16  | 15| 93.75 | 15 | 93.75 | 2  | 12.50 | 2  | 12.50 | 5  | 31.25 |
| Candida Krusei    | 7   | 7 | 100.00 | 7  | 100.00 | 1  | 14.29 | 1  | 14.29 | 2  | 28.57 |
| Total             | 157 | 151| 96.18 | 122| 77.71 | 12 | 7.64 | 12 | 7.64 | 38 | 24.20 |

**Table-1:** Correlation of Biofilm Producer and Antifungal Resistance

![Graph-1: Correlation of Biofilm Formation with Clinical Samples](image-url)
produces. Itraconazole (7.64%), Amphotericin-B (7.64%) and Nystatin (31.93%) were found to be quite sensitive antifungal drugs in biofilm producers.

**DISCUSSION**

In this study, on the basis of Corn Meal Agar morphology and CHROMagar method, maximum number of isolates were identified as *C. tropicalis* 145 (46.33%) followed by *C. albicans* 109 (34.82%), *C. parapsilosis* 33 (10.54%), *C. glabrata* 18 (5.75%) and *C. krusei* 8 (2.56%). On the basis of results obtained by different diagnostic methods, our study showed that out of total 313 isolates, *non albicans candida* species 204 (65.18%) were predominant isolates while *Candida albicans* was (34.82%) In our study this association was found to be statistically significant (P< 0.05). Similar results were obtained in study done by Manchanda et al. and Vijaya D et al. This change in pattern has been partly attributed to increased immune suppression resulting in higher numbers of susceptible immunocompromised patients, hospitalization especially in the ICUs, placement of central venous catheters and prophylactic use of antifungal agents in critically ill patients With the widespread use of broad-spectrum antimicrobials, the selective pressure exerted by the frequent use of antifungals also encourages the proliferation of drug-resistant *Non albicans Candida* species.

A biofilm is a community of micro-organisms and their extracellular polymers that are attached to a surface. The ability to form biofilms is associated with the pathogenicity and considered as an important virulence determinant during Candidiasis. Biofilms may help fungi in maintaining the role of commensal and pathogen by evading host immune mechanisms, resisting antifungal treatment and withstanding the competitive pressure from other organisms.

The TCP (Tissue Culture Plate Method) method was considered the gold standard for this study and compared with data from TM (Tube Method). In the TCP method, the number of isolates showing biofilm formation were 157/313 (50.16%) and non-biofilm producers were 156/313 (49.84%). Tube method detected 91/313 (29.07%) isolates as biofilm producers and 222/313 (70.93%) as non-biofilm producers. So, Tissue Culture Plate method (50.16%) was found to be more sensitive method for biofilm detection than Tube method (29.07%) and this finding was found to be statistically significant (P< 0.05). These observations were entirely in agreement with observations reported by Hassan et al., 2011, Ruzicka et al. 2004 and Mathur et al., 2006. When biofilm production was studied with respect to clinical samples, maximum biofilm production was obtained in blood samples 87/157 (55.41%) followed by respiratory secretion 21/157 (13.38%), Catheter tip 20/157 (12.74%), pus 13/157 (8.28%), vaginal 8/ 157 (5.10%), urine 7/157 (4.6%) and body fluids 1/157 (0.64%). The association of *Candida* biofilm production with different clinical samples was found to be statistically significant (P< 0.05). Similar results were obtained by Mohamed and Al-Ahmadely, 2013, Golia et al., 2011 and Singhai et al., 2012. *Candida* species are frequently found in the normal microbial flora of humans, which facilitates their encounter through implanted biomaterials and host surfaces. The devices become colonized by *Candida* which forms biofilm, the detachment of which can result in candidemia. Indwelling catheters therefore, represent a major risk factor associated with nosocomial *Candida* infections.

Biofilm formation was found to occur most frequently among *Non albicans Candida* species 122/157 (77.11%) than *C. albicans* 35/157 (22.29%). Among *Non albicans Candida*, *Candida tropicalis* 83/157 (52.86%) was most common *Candida* species to be isolated as biofilm producer followed by *C. Parapsilosis* (10.19%), *C. glabrata* (10.19%) and *C. krusei* (4.45%). Similar results were obtained by Shin et al., 2002, Tumbarello et al., 2007 and Kumar and Menon, 2006. When fungal isolates were tested for biofilm formation capacity, biofilm production was most commonly observed for isolates of *C. glabrata* 16/18 (88.9%) and *C. krusei* 7/8 (87.5%) followed by *C. tropicalis* 87/145 (57.2%), *C. parapsilosis* 16/33 (48.5%) and *C. albicans* 35/109 (32.1%) isolates. In our study, this association of biofilm formation capacity with different *Candida* species was found to be statistically significant (P< 0.05). Similar results were obtained by Tumbarello et al., 2007 and Kumar and Menon, 2006.

The susceptibility of *Candida* strains to antifungal drug was performed by disc diffusion method as per CLSI M44-A2 protocol. In the present study, Antifungal resistance among biofilm producers and non-biofilm producers was compared. Fluconazole (151/157; 96.18%) and Ketoconazole (122/157; 77.71%) were most common antifungal drugs to be resistant among biofilm producers. Itraconazole (12/157; 7.64%), Amphotericin-B (12/157; 7.64%) and Nystatin (38/157; 31.93%) were found to be less resistant antifungal drugs among biofilm producers (Table-1). Among non-biofilm producers, Maximum resistance was obtained for Fluconazole (11.54%) followed by Ketoconazole (0.64%). No resistance was found for Itraconazole, Amphotericin B and Nystatin among non-biofilm producers. Similar results were obtained in study done by Kuhn et al., 2002 and Tumbarello et al., 2007. So, biofilm production was found to be an important factor associated with antifungal resistance. Microorganisms organized in biofilms could become resistant to antifungals due to metabolic changes, reduction of their cell growth rate, expression of resistance genes and the presence of an extracellular matrix. Consequently, biofilm related infections are difficult to treat.

**CONCLUSION**

Biofilm production is an important risk factor for antifungal resistance. So, it is necessary to evaluate candida isolates for biofilm production. It will guide clinician for correct antifungal selection with exact doses that required. It will help in decrease the cost of treatment and proper management of patient.
REFERENCES

1. Chander J. In: A text book of Medical Mycology. 3rd edition, reprint march 2013. new delhi, chapter 20; p. 270–3.
2. Ghannoum MA, Clinical and Laboratory Standards Institute, editors. Method for antifungal disk diffusion susceptibility testing of yeasts; approved guideline. 2nd ed., replaces M44-A. Wayne, PA: Committee for Clinical Laboratory Standards; 2009. 25 p. (Documents / Clinical and Laboratory Standards Institute).
3. Gokse G, Cerkicioglu N, Yagci A. Acid proteinase, phospholipase and biofilm production of candida species isolated from blood culures. Mycopathologia. 2007;164:265–9.
4. Park K. Health information and basic medical statistics. In: Park’s textbook of preventive and social medicine. 21st ed. India: Bansari Das Bhanot; 2011. p. 779–92.
5. Manchanda V, Verma N, Bhalia P, Agarwal S. Yeast identification in routine clinical microbiology laboratory and its clinical relevance. Indian J Med Microbiol. 2011;29:172.
6. Vijaya D., Harsha T.R., Nagaratnamma T. Candida Speciation Using Chrom Agar. J Clinical Diagn Res. 2011;4:755–7.
7. Playford EG, Marriott D, Nguyen Q, Chen S, Ellis D, Slavin M, et al. Candidemia in nonneutropenic critically ill patients: risk factors for non-albicans Candida spp. Crit Care Med. 2008;36:2034–9.
8. Pfaller MA. Nosocomial Candidiasis: Emerging Species, Reservoirs, and Modes of Transmission. Clin Infect Dis. 1996;22:S89–94.
9. Hassan A, Usman J, Kaleem F, Omair M, Khalid A, Iqbal M. Evaluation of different detection methods of biofilm formation in the clinical isolates. Braz J Infect Dis. 2011;15:305–11.
10. Růžička F, Holá V, Votava M, Tejkalová R, Horvát R, Heroldová M, et al. Biofilm detection and the clinical significance of Staphylococcus epidermidis isolates. Folia Microbiol (Praha). 49(5):596.
11. Mathur T, Singhal S, Khan S, Upadhyay DJ, Fatma T, Rattan A. Detection of biofilm formation among the clinical isolates of Staphylococci: an evaluation of three different screening methods. Indian J Med Microbiol. 2006;24:25–9.
12. Mohamed S, Al-Ahmadey ZZ. Biofilm Formation and Antifungal Susceptibility of Candida Isolates from Various Clinical Specimens. Br Microbiol Res J. 2013;3:590–601.
13. Golia S, Hittinahalli V, Sangeetha KT, Vasudha CL. Study of biofilm formation as a virulence marker in candida species isolated from various clinical specimens. JEMDS. 2011;1:1238–46.
14. Singhai M, Malik A, Shahid M, Malik MA, Rowat V. Colonization of peripheral intravascular catheters with biofilm producing microbes: Evaluation of risk factors. Niger Med J. 2012;53(1).
15. Dominic RM, Shenoy S, Baliga S. Candida biofilms in medical devices. Evolving. trends. Kath Univ Med J. 2007;5:431–6.
16. Shin JH, Kee SJ, Shin MG, Kim SH, Shin DH, Lee SK, et al. Biofilm Production by Isolates of Candida Species Recovered from Nonneutropenic Patients: Comparison of Bloodstream Isolates with Isolates from Other Sources. J Clin Microbiol. 2002;40:1244–8.
17. Tumbarello M, Posteraro B, Trecarichi EM, Fiori B, Rossi M, Porta R, et al. Biofilm production by Candida species and inadequate antifungal therapy as predictors of mortality for patients with candidemia. J Clin Microbiol. 2007;45:1843–50.
18. Kumar CPG, Menon T. Biofilm production by clinical isolates of Candida species. Med Mycol. 2006;44:99–101.
19. Kuhn DM, Chandra J, Mukherjee PK, Ghannoum MA. Comparison of biofilms formed by Candida albicans and Candida parapsilosis on bioprosthetic surfaces. Infect Immun. 2002;70:878–88.

Source of Support: Nil; Conflict of Interest: None
Submitted: 25-03-2019; Accepted: 16-04-2019; Published: 20-05-2019